Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Baxter
Boehringer Ingelheim
Mallinckrodt
Queensland Health
Julphar
Fish and Richardson
Federal Trade Commission
Medtronic

Generated: July 23, 2018

DrugPatentWatch Database Preview

Naftifine hydrochloride - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for naftifine hydrochloride and what is the scope of naftifine hydrochloride freedom to operate?

Naftifine hydrochloride
is the generic ingredient in two branded drugs marketed by Taro Pharms, Tolmar, and Sebela Ireland Ltd, and is included in six NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naftifine hydrochloride has three patent family members in three countries.

There are eight drug master file entries for naftifine hydrochloride. Six suppliers are listed for this compound.
Pharmacology for naftifine hydrochloride
Ingredient-typeAllylamine
Drug ClassAllylamine Antifungal
Synonyms for naftifine hydrochloride
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethanamine Hydrochloride
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride
(E)-N-methyl-N-(1-naphthalenylmethyl)-3-phenyl-2-propen-1-amine hydrochloride
(E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine- hydrochloride
(E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride
(E)-N-Methyl-N-(3-phenyl-2-propen-1-yl)-1-naphthalenemethanamine Hydrochloride
(E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride
(E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride
1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, hydrochloride, (E)-
25UR9N9041
65473-14-5
A835130
AB0013289
AB02353
AC-1120
AC1NQY0T
AK326015
AKOS015895211
AN-15212
API0000683
AS-13296
AW 105-843
AW 105843
AW-105-843
AW-105843
BC679571
C-19785
C08072
C1162
CAS-65473-14-5
CCG-213447
CHEBI:7452
CHEMBL1200493
CS-2730
D00883
DSSTox_CID_25496
DSSTox_GSID_45496
DSSTox_RID_80915
DTXSID2045496
Exoderil
H72N880
H827
HMS1571E08
HY-B0518A
I06-0253
J10185
LS-176455
MFCD00059047
MLS002154136
MolPort-003-666-692
N-Methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride
N-trans-Cinnamyl-N-methyl-(1-naphthylmethyl)amine Hydrochloride
N-trans-Cinnamyl-N-methyl-(1-napphthylmethyl)amine hydrochloride
NAFT-600
NAFTIFENE HYDROCHLORIDE
naftifin hydrochloride, (E)-isomer
Naftifine (hydrochloride)
Naftifine HCl
Naftifine hydrochloride (USP)
Naftifine hydrochloride [USAN:USP]
Naftifine hydrochloride [USAN]
Naftifine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Naftifinehydrochloride
Naftifungin
Naftin
Naftin (TN)
NCGC00016908-01
NCGC00179332-03
NSC-760068
NSC760068
Pharmakon1600-01505446
s3156
SCHEMBL41356
SCHEMBL4932462
SMR001233443
SN 105843
SN-105843
SR-01000838853
SR-01000838853-2
ST51052723
Suadian
SureCN1649698
Tox21_110677
Tox21_110677_1
UNII-25UR9N9041

US Patents and Regulatory Information for naftifine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-002 Jan 13, 2012 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Taro Pharms NAFTIFINE HYDROCHLORIDE naftifine hydrochloride CREAM;TOPICAL 206901-001 Jan 6, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for naftifine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988 ➤ Sign Up ➤ Sign Up
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990 ➤ Sign Up ➤ Sign Up
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for naftifine hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,433,680 Topical compositions and methods for making and using same ➤ Sign Up
9,446,131 Topical compositions and methods for making and using same ➤ Sign Up
9,452,173 Topical compositions and methods for making and using same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Baxter
Chinese Patent Office
Federal Trade Commission
Daiichi Sankyo
Cerilliant
Accenture
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.